Analysts Offer Predictions for MiMedx Group FY2026 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for MiMedx Group in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will earn $0.40 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $13.00 target price on the stock. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

Separately, Wall Street Zen raised shares of MiMedx Group from a “hold” rating to a “buy” rating in a research note on Friday, June 6th.

MiMedx Group Stock Down 1.7%

Shares of MDXG opened at $6.42 on Tuesday. The company’s fifty day moving average is $6.77 and its two-hundred day moving average is $7.99. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market cap of $948.25 million, a PE ratio of 11.67 and a beta of 1.82.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.06. The firm had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.

Institutional Trading of MiMedx Group

A number of hedge funds and other institutional investors have recently made changes to their positions in MDXG. Paradigm Capital Management Inc. NY raised its holdings in shares of MiMedx Group by 0.5% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company’s stock worth $45,082,000 after purchasing an additional 22,131 shares in the last quarter. Cannell Capital LLC raised its holdings in shares of MiMedx Group by 1.1% in the 4th quarter. Cannell Capital LLC now owns 3,639,545 shares of the company’s stock worth $35,012,000 after purchasing an additional 40,235 shares in the last quarter. First Light Asset Management LLC raised its holdings in shares of MiMedx Group by 3.3% in the 1st quarter. First Light Asset Management LLC now owns 3,453,074 shares of the company’s stock worth $26,243,000 after purchasing an additional 109,213 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of MiMedx Group by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company’s stock worth $17,360,000 after purchasing an additional 280,327 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of MiMedx Group by 15.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company’s stock worth $17,338,000 after purchasing an additional 238,075 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

Insider Transactions at MiMedx Group

In other news, CEO Joseph H. Capper bought 200,000 shares of MiMedx Group stock in a transaction on Friday, May 2nd. The stock was purchased at an average cost of $6.34 per share, with a total value of $1,268,000.00. Following the purchase, the chief executive officer now directly owns 529,530 shares of the company’s stock, valued at approximately $3,357,220.20. This trade represents a 60.69% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.70% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.